1 Pipeline All Investors Need to Know

In this segment from Tuesday's Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass look at Merck (NYSE: MRK  ) , and why its pipeline is one investors should be excited about today.

Amazingly, Merck looks as though it will be the first to market with its PD1 immuno-oncology drug 3475, beating the seeming favorite Bristol-Myers Squibb's  (NYSE: BMY  ) nivolumab. David tells investors why he's excited about this coming megablockbuster and its potential for off-label use, as well as which key trials for the drug investors will want to watch for this year.

6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2942400, ~/Articles/ArticleHandler.aspx, 8/27/2014 11:34:26 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement